Focus: IDEAYA Biosciences is a public oncology-focused biotech developing personalized synthetic medicines, headquartered in South San Francisco with 501–1000 employees. The company emphasizes precision oncology with a diversified pipeline spanning uveal melanoma, lung cancer, pancreatic cancer, and solid tumors.
Profile data last refreshed 8h ago · AI intelligence enriched 2mo ago
Hot — 58 jobs added in 30d
Net +52 (58 new, 6 removed). Aggressive expansion phase.
High-risk, high-upside opportunity best suited for scientists and commercial professionals who tolerate pre-commercial risk in exchange for equity upside and precision oncology expertise.
Help build intelligence for IDEAYA Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from IDEAYA Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma - Morningstar
IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma Morningstar
IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer - PR Newswire
IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer PR Newswire
IDEAYA Biosciences (IDYA) Holds Near $36.96 as Precision Medicine Pipeline Takes Center Stage - Zigzag Correction - dars.gov.et
IDEAYA Biosciences (IDYA) Holds Near $36.96 as Precision Medicine Pipeline Takes Center Stage - Zigzag Correction dars.gov.et
IDEAYA Biosciences (IDYA) Holds Near $36.96 as Precision Medicine Pipeline Takes Center Stage - Modified Schiff - vinanet.vn
IDEAYA Biosciences (IDYA) Holds Near $36.96 as Precision Medicine Pipeline Takes Center Stage - Modified Schiff vinanet.vn
Uveal melanoma trial reports 6.9 months progression-free vs. 3.1 - Stock Titan
Uveal melanoma trial reports 6.9 months progression-free vs. 3.1 Stock Titan
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo